DBV Technologies Adds $25.5 Million in Series C
PE HUB -- Paris-based biotech company DBV Technologies has raised 19.4 million euros ($25.5 million) in a Series C round led by new investors InnoBio Fund and Lundbeckfond Ventures. Shire plc, ALTO Invest, Sofinnova Partners and ALK Abello also contributed to the round. DBV Technologies is developing products to combat food allergies such as peanut and milk. The company’s previous investors include Apax Partners, among others.